mavoglurant
Small moleculeexperimental
Mavoglurant (developmental code name AFQ-056) is an experimental drug candidate for the treatment of fragile X syndrome and other conditions. It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGluR5). — Wikipedia
Clinical trial activity
26 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
16
Phase 3
1
Phase 4
0
Earliest trial started Aug 1, 2006 (NCT00414856)
Timeline
Indications
Studied for
- Alcohol Drinking · Phase 2
- Alcohol-Induced Disorders · Phase 2
- Alcoholism · Early Phase 1
- Anti-Dyskinesia Agents · Phase 2
- Chorea · Phase 2
- Cigarette Smoking · Phase 1
- Cocaine-Related Disorders · Phase 2
- Dermatology · Phase 2
- Drugs, Investigational · Phase 2
- Dyskinesia, Drug-Induced · Phase 2
- Dyskinesias · Phase 2
- Fragile X Syndrome · Phase 2/Phase 3
- Gastroesophageal Reflux · Phase 1
- Huntington Disease · Phase 2
- Kidney Diseases · Phase 1
- Levodopa · Phase 2
- Liver Diseases · Phase 1
- Movement Disorders · Phase 2
- Obsessive Behavior · Phase 2
- Parkinson Disease · Phase 2
- Parkinsonian Disorders · Phase 2
Mechanism of action
- Metabotropic glutamate receptor 5ANTAGONIST
GRM5 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
COC(=O)N1CC[C@@H]2[C@H]1CCC[C@@]2(O)C#Cc1cccc(C)c1- Mol. weight
- 313.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaMavoglurant ↗
- ChEMBLCHEMBL3087515 ↗
Also known as
- afq056
- afq056
- afq056
- afq056
- mavoglurant
- mavoglurant
- mavoglurant
- mavoglurant
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06136195 | Phase 2 | Jan 1, 2024 | National Institute on Alcohol Abuse and Alcoholism (NIAAA), Yale University |
| NCT05203965 | Early Phase 1 (Phase 1) | May 17, 2022 | Yale University |
| NCT04771143 | Phase 1 | Jul 21, 2021 | National Institute on Drug Abuse (NIDA), Novartis |
| NCT03327792 | Phase 1 | Feb 7, 2018 | Yale University |
| NCT03341715 | Early Phase 1 (Phase 1) | Jan 17, 2018 | Yale University |
| NCT03242928 | Phase 2 | Dec 4, 2017 | Novartis |
| NCT02920892 | Phase 2 | Jun 5, 2017 | National Institute of Neurological Disorders and Stroke (NINDS), Rush University |
| NCT01813019 | Phase 2 | Nov 1, 2013 | Novartis |
| NCT01491529 | Phase 2 | Apr 1, 2012 | Novartis |
| NCT01482143 | Phase 1 | Mar 1, 2012 | Novartis |
| NCT01491932 | Phase 2 | Mar 1, 2012 | Novartis |
| NCT01433354 | Phase 2/Phase 3 (Phase 3) | Nov 1, 2011 | Novartis |
| NCT01385592 | Phase 2 | Nov 1, 2011 | Novartis |
| NCT01348087 | Phase 2 | Aug 1, 2011 | Novartis |
| NCT01456663 | Phase 1 | May 1, 2011 | Novartis |
| NCT01357239 | Phase 2 | May 1, 2011 | Novartis |
| NCT01442259 | Phase 1 | Jan 1, 2011 | Novartis |
| NCT01253629 | Phase 2 | Nov 1, 2010 | Novartis |
| NCT01173731 | Phase 2 | Oct 1, 2010 | Novartis |
| NCT01092065 | Phase 2 | Mar 1, 2010 | Novartis |
Showing 20 of 26 trials
Page 1 / 2
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Novartis | For profit | 21 | 21 | 3 | 2006 |
| Yale University | Academic/Hospital | 4 | 4 | 2 | 2018 |
| National Institute of Neurological Disorders and Stroke (NINDS) | Government | 1 | 0 | 1 | 2017 |
| National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Government | 1 | 0 | 1 | 2024 |
| National Institute on Drug Abuse (NIDA) | Government | 1 | 0 | 1 | 2021 |
| Rush University | Academic/Hospital | 1 | 1 | 1 | 2017 |
6 organizations
Page 1 / 1